Results 151 to 160 of about 2,746 (190)
Some of the next articles are maybe not open access.
Dienogest in the treatment of endometriosis
Expert Opinion on Pharmacotherapy, 2014Dienogest (DNG) is an oral progestin, derivative of 19-nortestosterone, that has recently been introduced for the treatment of endometriosis.This review examines the clinical efficacy, safety and tolerability of DNG in the treatment of endometriosis.
Bizzarri N +9 more
openaire +5 more sources
pharma-kritik, 2022
Mit Dienogest als Monopräparat steht eine vergleichsweise gut dokumentierte Behandlungsoption bei Endometriose zur Verfügung. Ob sich dieses Gestagen aber signifikant besser auf die Endometriose-bedingten Schmerzen auswirkt als andere Therapien (z.B. andere Gestagene), ist bisher nicht nachgewiesen.
openaire +1 more source
Mit Dienogest als Monopräparat steht eine vergleichsweise gut dokumentierte Behandlungsoption bei Endometriose zur Verfügung. Ob sich dieses Gestagen aber signifikant besser auf die Endometriose-bedingten Schmerzen auswirkt als andere Therapien (z.B. andere Gestagene), ist bisher nicht nachgewiesen.
openaire +1 more source
Drugs, 2009
Estradiol valerate/dienogest is an oral contraceptive for women that combines the natural estrogen estradiol with the 19-nortestosterone derivative dienogest in a four-phasic formulation. Estradiol valerate/dienogest demonstrated contraceptive efficacy in a large (n = 1377), noncomparative, multicentre study in women aged 18-50 years, with 13 ...
Sheridan M, Hoy, Lesley J, Scott
openaire +2 more sources
Estradiol valerate/dienogest is an oral contraceptive for women that combines the natural estrogen estradiol with the 19-nortestosterone derivative dienogest in a four-phasic formulation. Estradiol valerate/dienogest demonstrated contraceptive efficacy in a large (n = 1377), noncomparative, multicentre study in women aged 18-50 years, with 13 ...
Sheridan M, Hoy, Lesley J, Scott
openaire +2 more sources
Drugs, 2010
Dienogest (Visanne®) is a synthetic oral progestogen with unique pharmacological properties that is indicated at a dosage of 2 mg/day for the treatment of endometriosis. It is generally highly selective for the progesterone receptor and displays strong progestational effects and moderate antigonadotrophic effects, but no androgenic, glucocorticoid or ...
openaire +2 more sources
Dienogest (Visanne®) is a synthetic oral progestogen with unique pharmacological properties that is indicated at a dosage of 2 mg/day for the treatment of endometriosis. It is generally highly selective for the progesterone receptor and displays strong progestational effects and moderate antigonadotrophic effects, but no androgenic, glucocorticoid or ...
openaire +2 more sources
Endometriosis: the effects of dienogest.
BMJ clinical evidence, 2015Ectopic endometrial tissue is found in 2% to 6% of women of reproductive age, in up to 60% of those with dysmenorrhoea, and in up to 30% of women with subfertility, with a peak incidence at around 40 years of age. However, symptoms may not correlate with laparoscopic findings.We conducted a systematic review and aimed to answer the following clinical ...
FERRERO, SIMONE +3 more
openaire +3 more sources
Ethinylestradiol/Dienogest in Oral Contraception
Drugs, 2010The low-dose combined oral contraceptive of ethinylestradiol 30 microg and dienogest 2 mg was launched in Germany in 1995, and is now the most commonly prescribed oral contraceptive in this country. Dienogest is a novel 19-nortestosterone-derived progestin with a unique pharmacokinetic and pharmacological profile, including antiandrogenic properties ...
openaire +2 more sources